Purpose The aim of this study was to investigate whether relevant plasma levels of dFdU could be detected during concurrent chemoradiation (CRT) with low doses of dFdC administered in patients with head and neck cancer and to assess the toxicity related to dose. Methods dFdC was administered at doses of 5 mg/m² twice weekly or 10, 50, or 100 mg/m² weekly. Plasma concentrations of dFdU were determined daily for 7 days after the Wrst administration and before each administration, thereafter. A high-performance liquid chromatographic method was used. During CRT, skin and mucosal toxicity were scored weekly according to the RTOG toxicity scoring system. Results Eight patients were sampled at the 10-50 mg/m² dose and nine at the 5-100 mg/m² dose. dFdU levels were in the micromolar range, inducing RS in vitro. There was a strong correlation between the area under the curve of dFdU and the dose of dFdC (r = 0.803, P < 0.001) and a weak correlation between trough concentrations and total dose of dFdC (r = 0.408, P = 0.017). Duration of severe mucositis correlated with dFdC dose.
Introduction
Gemcitabine (2Ј,2Ј-diXuorodeoxycytidine; dFdC) is a Xuorinated pyrimidine nucleoside analog [1] with antitumor activity against a wide variety of tumors, including head and neck cancer [2] . Gemcitabine is a prodrug that requires several steps of phosphorylation to yield the active metabolites, diXuorodeoxycytidine diphosphate (dFdCDP) and diXuorodeoxycytidine triphosphate (dFdCTP), which target DNA and RNA and are presumably responsible for the cytotoxic eVect [1, 3, 4] . dFdCTP is incorporated into DNA and inhibits DNA polymerase processing, whereas dFd-CDP interferes with the enzyme ribonucleotide reductase, causing depletion of deoxynucleotide triphosphate necessary for DNA synthesis. The rate-limiting step is the phosphorylation of gemcitabine into diXuorodeoxycytidine monophosphate by deoxycytidine kinase [5] [6] [7] . In addition to its cytotoxic eVects, gemcitabine has potent radiosensitizing properties, as shown both in preclinical and in clinical settings, with in vitro radioenhancement factors up to three, depending upon schedule and concentration [8] . The current evidence suggests that accumulation in the S phase of the cell cycle, depletion of dATP pools, reduction of apoptotic threshold, inhibition of DNA synthesis and reduction of DNA repair might contribute to, or might even be essential for gemcitabine-mediated radiosensitization [9] [10] [11] [12] [13] .
The radiosensitizing properties of gemcitabine have been exploited in patients with pancreatic cancer [8, 14, 15] , other gastrointestinal cancers [8] , lung cancer [8] , cancer of the uterine cervix [16, 17] , and head and neck cancer [18] [19] [20] . In patients, gemcitabine is rapidly cleared from the plasma with a half-life of only a few minutes [21, 22] . It is deaminated by deoxycytidine deaminase to its main metabolite diXuorodeoxyuridine (dFdU), which has little cytotoxic activity at clinically relevant levels [23] . However, dFdU has clear radiosensitizing properties in vitro when given in micromolar ranges [23] and has the additional advantage of a prolonged half-life [21, 22] . Our hypothesis was that the radiosensitizing potential of dFdU could be of clinical importance even when very low doses of gemcitabine are given, when this metabolite would be continuously available in plasma in concentrations that in vitro are inducing radiosensensitization. We therefore measured dFdU concentrations in plasma in patients with tumors in the head and neck region who were treated with low-dose gemcitabine during chemoradiation.
Patients and methods

Study objectives
The aims of this study were to investigate whether relevant plasma levels of dFdU could be detected during concurrent chemoradiation with low doses of gemcitabine administered in patients with cancer in the head and neck region and to assess the acute toxicity related to gemcitabine dose.
Eligibility criteria
Included were patients who were considered Wt enough by the multidisciplinary team of dedicated head and neck surgeons, radiotherapists, and medical oncologists to receive gemcitabine-based concurrent chemoradiation for tumors located in the head and neck region, with no restrictions regarding the site of the tumor, the histology, the disease setting (either after induction chemotherapy or as deWnitive chemoradiation or adjuvantly after surgery), age, performance status, or organ functions (serum creatinine, liver enzymes). Patients were informed about the pros and cons of gemcitabine-based chemoradiation and were to give informed consent.
Treatment
Concurrent chemoradiation was given either as deWnitive treatment alone or after induction chemotherapy or in the postoperative setting. The planned irradiation dose was 66-70 Gy in 33-35 fractions of 2 Gy over 6.5-7 weeks.
Gemcitabine was administered over 30 min within 2 h before irradiation at doses of 5 mg/m² twice weekly or 10, 50, or 100 mg/m² weekly along with radiation therapy.
Blood sampling and storage
Ten milliliter blood was drawn into a lithium heparin tube every 24 h for 7 days, starting 24 h after the Wrst administration of gemcitabine, and before each administration thereafter. Hundred microliter of a tetrahydrouridine (THU) solution 10% was added. The mixture was vortexed immediately at 3,941 rounds per minute for 15 min, and the plasma was stored at minus 20°C.
Analysis of dFdU in plasma
A high-performance liquid chromatographic (HPLC) method was used and validated for the determination of dFdU in human plasma. Floxuridine (5-Xuoro-2Ј-deoxyuridine was used as an internal standard. Tetrahydrouridine (THU) was used to prevent the deamination of gemcitabine to dFdU after sampling. Standard samples of blank plasma were spiked with dFdU (50-50,000 ng) and extracted in the same way as the other samples and used for a calibration curve. Separation was achieved isocratic on a Chrompack Sperisorb ODS-2 column (5 m, 4.6 £ 250 mm). The mobile phase was Pic B7 (Water Corporation) in a 10% methanol solution (pH 3.1) with a Xow rate of 1.0 ml/min. The analytes were detected by ultraviolet detection at 270 nm. The limit of detection was about 50 ng/ml for dFdU. Within-run and between-run precisions were less than 10%, and average accuracies were between 90 and 110%.
Plasma extraction
For the sample pretreatment procedure, 100 l internal standard work solution and 50 l of a THU solution (10 mg/ml) were added to 200 l of plasma. After vortexing, the sample was treated with 6 ml of iso-propanol (15%) in ethyl acetate and mixed thoroughly. After centrifugation, the organic phase was transferred to a glass tube and evaporated till dry by vacuum centrifugation. The residue was redissolved in 1 ml of the mobile phase (a 5 £ dilution) and Wltered over a 0.45-m PVDF HPLC Wlter (Acrodisc, Waters Corporation) for HPLC injection (20 l).
Calculations and toxicity scoring
The dFdU area under the curve during the Wrst week of treatment was calculated using the trapezoid method. The mean trough concentration of dFdU for each patient and the median of the mean trough concentrations for each dose level were calculated.
The acute mucosal and skin toxicity during the chemoradiation were scored weekly according to the RTOG Acute Radiation Morbidity Scoring Criteria [24] by the same very experienced radiotherapist who was blinded to the gemcitabine dose. The sum of the number of weeks with grade 3 or 4 toxicity during the treatment was calculated for each patient.
Statistics
Correlations were calculated using the Spearman's rho test. Means were compared using the one-way ANOVA after performing a Levene's test in order to exclude signiWcant variances within groups. All statistical analyses were 
Results
Patient population
Thirty-four patients were included in the study between October 2006 and June 2008. Patient, tumor, and treatment characteristics are summarized in Table 1 . The results are summarized in Tables 2 and 3 . Eight of the 34 patients received chemoradiation in the postoperative setting, Wve in the 5 mg/m 2 dose group and one each in the other dose groups. Therefore, the patients in the 5 mg/m 2 dose group received proportionally a lower radiation dose than the other three groups. The area under the concentration-time curve (AUC) of dFdU by dose level of dFdC during the Wrst week of treatment is shown in Fig. 1 . We found a clear correlation between the AUC of dFdU and the gemcitabine dose level (Spearman's rho = 0.805; P < 0.0001). Figure 2 shows the dFdU concentrations versus gemcitabine dose for each day during the Wrst week of treatment. Of notice, in the 5 mg/m 2 dose group, patients received the second administration after the trough concentrations measured on day 4. Figure 3 shows the means and the 95% conWdence intervals of all dFdU trough concentrations by dFdC dose (mg/m²). Mean dFdU trough concentrations were not signiWcantly diVerent between the four diVerent dose levels. DiXuorodeoxyuridine remained detectable in plasma of the majority of patients even after doses as low as 10 mg/m² once weekly or 5 mg/m² twice weekly. However, there was a wide interpatient variation as illustrated by the wide conWdence intervals.
Skin and mucosal toxicity is summarized in Table 4 . The majority of patients developed grade 3 or 4 mucositis and grade 2 radiodermatitis, regardless of the dFdC dose. However, there was a correlation between the sum of the number of weeks with grade 3 or 4 mucositis during the treatment and the gemcitabine dose given during irradiation ( Fig. 4 ; Spearman's rho: 0.592; P < 0.0001). Hematologic toxicity is summarized in Table 5 . Grade 3 or 4 hematological toxicity was rare and occurred only in patients who had received prior induction chemotherapy before the concurrent use of low-dose gemcitabine and radiation.
Discussion
DiXuorodeoxyuridine remained detectable in plasma of our patients, even after administration of doses of gemcitabine as low as 10 mg/m² once weekly or 5 mg/m² twice weekly. There were substantial interpatient variations at the four studied dose levels, reXecting the wide variation in pharmacokinetics and pharmacodynamics of the drug [25] [26] [27] [28] . Indeed gene polymorphisms were reported for several enzymes involved in dFdC metabolism, including deoxycytidine kinase and cytidine deaminase [29] [30] [31] . DiXuorodeoxyuridine was previously shown to be a very potent radiosensitizer in vitro in multiple cell lines after exposure for only 24 h, even at a concentration of 10 M [23] . In most of our patients, we measured trough concentrations within the micromolar range. Moreover, if we take into account that the elimination of dFdU after the second and subsequent administrations follows the same pattern as after the Wrst administration, considerably higher levels of dFdU were probably present for several days during the radiation in the majority of patients, even at these low gemcitabine dosages. Although multiple factors most likely are responsible for the radiosensitizing eVect of dFdC [9] [10] [11] [12] [13] , the sustained presence of dFdU in the blood could at least partly explain the often dramatic radioenhancement which is observed after administration of gemcitabine, despite short half-life of the parent drug. We are fully aware of the limitations of this study due to the low number of patients in each treatment cohort and the diVerences in age, tumor type, tumor site, and tumor stage. However, with these limitations in mind, we observed no correlation between the dose or dose level and the maximum grade of skin and/or mucosal toxicity. In contrast, when we took into account the duration of grade 3 or 4 toxicity during the treatment, a signiWcant correlation was observed between the weeks spent with grade 3 or 4 mucositis and dose level. The heterogeneity of the patient and treatment characteristics precludes any evaluation of the long term toxicity related to gemcitabine dose.
Concomitant chemoradiation with low doses of gemcitabine induces little hematologic toxicity, even after prior induction chemotherapy. Renal toxicity is extremely rare, even at standard cytotoxic doses [32] . When used as a single agent, gemcitabine does not cause neurotoxicity or ototoxicity [32] . These characteristics of the compound can be extremely useful in patients previously treated with cisplatin (e.g., after induction chemotherapy), or in patients with preexisting neuropathy, hearing loss or impaired renal function. Nevertheless, caution is warranted when patients are treated with severe impairment of the renal function, as elimination of dFdU is dependent on renal excretion and can accumulate in patients with renal failure [33, 34] .
The parameters in this study, as summarized in Table 2 , are of course not suYcient to discuss the complete pharmacokinetic proWle of gemcitabine and dFdU.
We conclude that during chemoradiation with 10-100 mg/m 2 of gemcitabine weekly or 5 mg/m 2 twice weekly, dFdU remains detectable at potentially radiosensitizing concentrations. Such gemcitabine doses are signiWcantly correlated with the AUC of dFdU and the duration of severe mucositis. 
